Dapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients

Yazdanyar, Shiva; Boer, Jurr; Ingvarsson, G.; Szepietowski, Jacek C.; Jemec, Gregor B. E.

doi:10.1159/000329023

Cited by 109 publications

(59 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All five patients showed improvement after 4-12 weeks of treatment. In a later series of 24 patients treated with 50-200 mg per day, nine patients showed slight to clinically significant improvement, whereas the other 15 did not respond to dapsone therapy [95].…”

Section: Dapsonementioning

confidence: 92%

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent inflammatory nodules mostly located in the armpits and groin. Over the years multiple treatments for HS have been proposed; however, to date a cure is still lacking. In this update we provide an overview of most drug treatments reported on for HS, where possible with their mode of action and side effects. In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracyclines are a first-line systemic option in more widespread or severe cases, followed by the combination of clindamycin and rifampicin. However, the recurrence rate is high after discontinuation of clindamycin plus rifampicin combination therapy. Long-term treatment with retinoids, especially acitretin is feasible, although teratogenicity has to be taken into account in females of reproductive age. Multiple antiinflammatory drugs have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their effectiveness in HS is based on small case series with varying results. If most common treatments have failed, biologics (e.g., infliximab or adalimumab) are the next step. Although not addressed in this review, surgical interventions are often needed to achieve remission. Key PointsHidradenitis suppurativa (HS) is a chronic inflammatory skin disease without a cure.Antibiotics (topical or oral) are often the first treatment option for HS.In cases of more extensive or therapy-resistant HS, biologicals (e.g., infliximab or adalimumab) are a good therapeutic option.

show abstract

Section: Dapsonementioning

confidence: 92%

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

show abstract

“…Used topically and systemically as anti-inflammatories, antibiotics may also decrease odor and reduce pain. Topical clindamycin 1% solution twice a day and oral antibiotics (doxycycline, minocycline, erythromycin, amoxicillin plus clavulanic acid, rifampicin, cephalosporins, and others) have been used, as has dapsone [32]. [14].…”

Section: Antibioticsmentioning

confidence: 99%

Hidradenitis suppurativa

Margesson

Danby

2014

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

Hidradenitis suppurativa is a chronic relapsing disorder of the folliculopilosebaceous units (FPSUs). Its negative impact on quality of life is extreme, mainly due to the lack of early recognition, accurate diagnosis, and appropriate management. The support structure of the FPSUs is defective. Under the influence of endogenous reproductive hormones, exogenous hormones, androgens and their precursors in dairy products, and other dietary factors, the follicular unit is plugged and distended by retained keratin. Friction, shearing forces, and pressure lead to rupture and leakage of the ductal contents from the weakened FPSU, causing an inflammatory reaction mediated mainly by the innate immune system. Therapy requires patient comprehension and cooperation, counseling, aggressive hormonal and dietary modification, avoidance of the trauma that leads to rupture, active multimodal anti-inflammatory therapy, and early unroofing and debridement. The full therapeutic program is needed to avoid the aggressive surgery required if the condition is not diagnosed early and managed appropriately.

show abstract

“…The dose range used is wide (25–200mg/day), with adverse haematological and neurological effects increasing at higher doses. A retrospective case review of 24 patients treated with dapsone found a clinically significant improvement in six and slight improvement in a further three 30. Recurrence after cessation of treatment was rapid and none of the four patients with advanced disease experienced improvement.…”

Section: Clinical Efficacymentioning

confidence: 99%

Management of hidradenitis suppurativa

2016

DTB

View full text Add to dashboard Cite

Hidradenitis suppurativa is a recurring chronic inflammatory debilitating skin disease of the hair follicle that usually presents with painful, deep-seated and inflamed lesions in the apocrine gland-bearing areas of the body. The lesions often progress to become chronic with purulent discharge, sinus formation and scarring. Hidradenitis suppurativa is associated with systemic comorbidities, including metabolic syndrome and inflammatory bowel disease.(1) Long-term treatment is often necessary and requires coordination between primary care, dermatologists and surgeons. However, there is a lack of good quality evidence and a paucity of authoritative guidance on treatment strategies. In this article, we review the diagnosis and management of hidradenitis suppurativa and discuss some new developments, including the use of cytokine modulators.

show abstract

Dapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients

Cited by 109 publications

References 49 publications

An Update on Medical Treatment Options for Hidradenitis Suppurativa

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Hidradenitis suppurativa

Management of hidradenitis suppurativa

Contact Info

Product

Resources

About